Drug Profile
Glycoprotein therapeutic - Nanomix Corporation
Alternative Names: IpoxynLatest Information Update: 17 May 2023
Price :
$50
*
At a glance
- Originator Boston Therapeutics
- Developer Nanomix Corporation
- Class Glycoproteins
- Mechanism of Action Oxygen carriers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Suspended Anaemia; Cardiovascular disorders; Peripheral ischaemia
Most Recent Events
- 07 Jun 2017 Boston Therapeutics is seeking partners for funding the development of glycoprotein therapeutic as of 28 Mar 2017 .
- 28 Mar 2017 Suspended - Preclinical for Peripheral ischaemia, Cardiovascular disorders and Anaemia in USA until Boston Therapeutics can secure funds for the compound (IV)
- 30 May 2014 Preclinical development is ongoing